Oregon Public Employees Retirement Fund raised its stake in shares of Boston Scientific Co. (NYSE:BSX – Free Report) by 0.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 126,259 shares of the medical equipment provider’s stock after buying an additional 1,056 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Boston Scientific were worth $9,723,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently modified their holdings of BSX. Sierra Summit Advisors LLC acquired a new stake in Boston Scientific in the fourth quarter worth $8,038,000. TD Asset Management Inc grew its stake in Boston Scientific by 10.7% in the fourth quarter. TD Asset Management Inc now owns 1,615,932 shares of the medical equipment provider’s stock valued at $93,417,000 after acquiring an additional 155,565 shares during the period. BI Asset Management Fondsmaeglerselskab A S raised its position in shares of Boston Scientific by 225.6% during the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 105,671 shares of the medical equipment provider’s stock worth $7,237,000 after purchasing an additional 73,219 shares during the period. BDF Gestion acquired a new position in shares of Boston Scientific in the 2nd quarter valued at approximately $3,570,000. Finally, Precision Wealth Strategies LLC acquired a new position in shares of Boston Scientific in the fourth quarter valued at approximately $956,000. 89.07% of the stock is owned by institutional investors.
Boston Scientific Trading Down 0.8 %
Shares of Boston Scientific stock opened at $81.14 on Wednesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.61 and a quick ratio of 1.14. The business has a fifty day simple moving average of $77.12 and a two-hundred day simple moving average of $73.25. Boston Scientific Co. has a 1 year low of $48.35 and a 1 year high of $82.10. The company has a market capitalization of $119.04 billion, a price-to-earnings ratio of 68.18, a P/E/G ratio of 2.71 and a beta of 0.78.
Insider Buying and Selling
In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $74.12, for a total value of $517,579.96. Following the completion of the transaction, the executive vice president now directly owns 40,188 shares of the company’s stock, valued at approximately $2,978,734.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 20,949 shares of company stock valued at $1,627,877 over the last 90 days. 0.50% of the stock is owned by corporate insiders.
Analyst Ratings Changes
Several equities research analysts recently commented on BSX shares. BTIG Research upped their target price on shares of Boston Scientific from $80.00 to $84.00 and gave the stock a “buy” rating in a research note on Monday, July 15th. Raymond James increased their price objective on Boston Scientific from $85.00 to $91.00 and gave the stock a “strong-buy” rating in a report on Thursday, July 25th. Argus upped their price target on Boston Scientific from $80.00 to $95.00 and gave the stock a “buy” rating in a research report on Tuesday, May 28th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Boston Scientific from $73.00 to $78.00 and gave the stock a “hold” rating in a research report on Thursday, July 25th. Finally, TD Cowen raised their target price on shares of Boston Scientific from $77.00 to $86.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. Three equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $85.24.
View Our Latest Analysis on Boston Scientific
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
See Also
- Five stocks we like better than Boston Scientific
- 3 Tickers Leading a Meme Stock Revival
- Homebuilders Poised for a Breakout: Top Stocks to Watch
- What is the S&P 500 and How It is Distinct from Other Indexes
- 3 Bargain-Priced Growth Stocks for Fall 2024
- Stock Dividend Cuts Happen Are You Ready?
- 4 Stocks That Boosted Their Bottom Line with Beef
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.